Details of the Drug Combination

General Information of Drug Combination (ID: DC81IF5)

• Drug Combination Name: BIO-300 + Triapine
• Indication: Anaplastic large cell lymphoma; Status: Investigative [1]
• Component Drugs:
  BIO-300 (DMJ7NVI): N.A.
  Triapine (DM7XZY5): Small molecular drug
• High-throughput Screening Result:
  Testing Cell Line: SR
  Zero Interaction Potency (ZIP) Score: 18.97
  Bliss Independence Score: 14.45
  Loewe Additivity Score: 7.59
  LHighest Single Agent (HSA) Score: 15.6

Molecular Interaction Atlas of This Drug Combination

Indication(s) of BIO-300

Disease Entry	ICD 11	Status	REF
Solid tumour/cancer	2A00-2F9Z	Phase 1/2	[2]
Rheumatoid arthritis	FA20	Phase 1	[3]

Indication(s) of Triapine

Disease Entry	ICD 11	Status	REF
Nerve injury	ND56.4	Phase 2	[4]

Triapine Interacts with 1 DTT Molecule(s)

DTT Name	DTT ID	UniProt ID	Mode of Action	REF
Ribonucleoside-diphosphate reductase M2 (RRM2)	TTBWDI0	RIR2_HUMAN	Modulator	[4]

Triapine Interacts with 2 DOT Molecule(s)

DOT Name	DOT ID	UniProt ID	Mode of Action	REF
Histone H2AX (H2AX)	OT18UX57	H2AX_HUMAN	Increases Expression	[6]
Thioredoxin-dependent peroxide reductase, mitochondrial (PRDX3)	OTLB2WEU	PRDX3_HUMAN	Increases Oxidation	[5]

Test Results of This Drug Combination in Other Disease Systems

Indication	DrugCom ID	Cell Line	Status	REF
Clear cell renal cell carcinoma	DCZQF4S	TK-10	Investigative	[1]
Clear cell renal cell carcinoma	DCZ0ID1	CAKI-1	Investigative	[1]
Papillary renal cell carcinoma	DCVWHZU	ACHN	Investigative	[1]
Breast adenocarcinoma	DCXEIWM	MDA-MB-468	Investigative	[7]
Carcinoma	DCUIYU8	RXF 393	Investigative	[7]
Carcinoma	DCZB2LH	MCF7	Investigative	[7]
Invasive ductal carcinoma	DCUI8WP	BT-549	Investigative	[7]
Adenocarcinoma	DCVE6FS	DU-145	Investigative	[8]
Adenocarcinoma	DCPVFSW	SW-620	Investigative	[8]
High grade ovarian serous adenocarcinoma	DC2P7ZH	OVCAR-8	Investigative	[8]
Lung adenocarcinoma	DCFDNOR	MDA-MB-231	Investigative	[8]
Non-small cell lung carcinoma	DCWJSDT	HOP-92	Investigative	[8]
Pleural epithelioid mesothelioma	DCRC62Y	NCI-H226	Investigative	[8]

References

• [1] Recurrent recessive mutation in deoxyguanosine kinase causes idiopathic noncirrhotic portal hypertension.Hepatology. 2016 Jun;63(6):1977-86. doi: 10.1002/hep.28499. Epub 2016 Mar 31.
• [2] Clinical pipeline report, company report or official report of Humanetics.
• [3] Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
• [4] PAN-811 inhibits oxidative stress-induced cell death of human Alzheimer's disease-derived and age-matched olfactory neuroepithelial cells via suppression of intracellular reactive oxygen species. J Alzheimers Dis. 2009;17(3):611-9.
• [5] The iron-chelating drug triapine causes pronounced mitochondrial thiol redox stress. Toxicol Lett. 2011 Mar 5;201(2):130-6. doi: 10.1016/j.toxlet.2010.12.017. Epub 2010 Dec 31.
• [6] Distinct mechanisms of cell-kill by triapine and its terminally dimethylated derivative Dp44mT due to a loss or gain of activity of their copper(II) complexes. Biochem Pharmacol. 2014 Oct 1;91(3):312-22. doi: 10.1016/j.bcp.2014.08.006. Epub 2014 Aug 15.
• [7] Biologically active neutrophil chemokine pattern in tonsillitis.Clin Exp Immunol. 2004 Mar;135(3):511-8. doi: 10.1111/j.1365-2249.2003.02390.x.
• [8] Loss of function mutations in VARS encoding cytoplasmic valyl-tRNA synthetase cause microcephaly, seizures, and progressive cerebral atrophy.Hum Genet. 2018 Apr;137(4):293-303. doi: 10.1007/s00439-018-1882-3. Epub 2018 Apr 24.